cancer-treatment

Documents about cancer-treatment

• Social Network Characteristics as Predictors of Opioid Use Disorder Treatment Utilization among People Who Use Drugs with Hepatitis C Infections in Baltimore, MD#337307Figshare
• A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma#432870ClinicalTrials.gov
• A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma#683128ClinicalTrials.gov
• Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of D#164844Unpaywall
• Additional file 6 of Successful treatment of an NDM-5-producing, carbapenem-resistant Salmonella Kentucky ST198 infection with aztreonam and ceftazidime-avibactam in a patient with acute erythroid leukemia: a case report#337340Figshare
• Additional file 5 of Successful treatment of an NDM-5-producing, carbapenem-resistant Salmonella Kentucky ST198 infection with aztreonam and ceftazidime-avibactam in a patient with acute erythroid leukemia: a case report#337342Figshare
• Additional file 4 of Successful treatment of an NDM-5-producing, carbapenem-resistant Salmonella Kentucky ST198 infection with aztreonam and ceftazidime-avibactam in a patient with acute erythroid leukemia: a case report#337343Figshare
• Additional file 3 of Successful treatment of an NDM-5-producing, carbapenem-resistant Salmonella Kentucky ST198 infection with aztreonam and ceftazidime-avibactam in a patient with acute erythroid leukemia: a case report#337344Figshare
• Additional file 2 of Successful treatment of an NDM-5-producing, carbapenem-resistant Salmonella Kentucky ST198 infection with aztreonam and ceftazidime-avibactam in a patient with acute erythroid leukemia: a case report#337345Figshare
• Additional file 1 of Successful treatment of an NDM-5-producing, carbapenem-resistant Salmonella Kentucky ST198 infection with aztreonam and ceftazidime-avibactam in a patient with acute erythroid leukemia: a case report#337347Figshare
• A comprehensive assessment of cholinesterase inhibitors for the treatment of Alzheimer’s disease based on drug selection recommendations for Chinese Medical Institutions#436111Figshare
• Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)#474773ClinicalTrials.gov
• Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines#379143Repositorio Institucional de la Universidad de Burgos (RIUBU)
• Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC)#452015HAL (France)
• Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma#307462ClinicalTrials.gov
• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)#417526ClinicalTrials.gov
• Secondary / Tertiary Amines in the Generic Polymedication as Milestone for Drug / Food – Related Nitroso Formation and Subsequent Photocarcinogenicity / Skin Cancer Development in Humans: Advancement / Rotation Flaps as Treatment Choice#427386HAL (France)
• A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation#435749ClinicalTrials.gov
• CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer#481764ClinicalTrials.gov
• Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies#623512ClinicalTrials.gov
• Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma#201758ClinicalTrials.gov
• Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study#411390ClinicalTrials.gov
• Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer#127573ClinicalTrials.gov
• Investigation on the efficacy of luliconazole-loaded nanostructured lipid carriers for the treatment of skin and nail fungal infection: <i>In-vitro, in-vivo,</i> and <i>ex-vivo</i> characterization#609489Figshare
• ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial#801025ClinicalTrials.gov
• PET With Respiratory Gating Technique in Evaluation of Response and Normal Tissue Effect in Thoracic Cancer#802242ClinicalTrials.gov
• HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant#67875ClinicalTrials.gov
• CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer#343844ClinicalTrials.gov
• A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk#121342ClinicalTrials.gov
• Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology#161134Zenodo (CERN)
• Correlates of lifetime blunt/spliff use among cigarette smokers in substance use disorders treatment#609418eScholarship
• Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma#343842ClinicalTrials.gov
• Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial#467610ClinicalTrials.gov
• Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia#620113eScholarship
• Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor#802918ClinicalTrials.gov
• PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol#630425HAL (France)
• Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia#804087ClinicalTrials.gov
• A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma#18613ClinicalTrials.gov
• Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma#234431ClinicalTrials.gov
• Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma#444887ClinicalTrials.gov
• ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma#160340ClinicalTrials.gov
• Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma#353277ClinicalTrials.gov
• <p>The expression levels of apoptotic genes (<i>Bcl2</i>, <i>Bax</i>, <i>Caspase3</i>, and <i>P53</i>) in HT-29 cells were analyzed following treatment with SP from the red seaweed <i>G. corticata</i> at ½ IC₅₀ and ¼ IC₅₀ concentrations.</p>#195577Figshare
• Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides#806764ClinicalTrials.gov
• CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia#803604ClinicalTrials.gov
• Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer#356488ClinicalTrials.gov
• Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma#325290ClinicalTrials.gov
• Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma#806348ClinicalTrials.gov
• Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers#802520ClinicalTrials.gov
• Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment#805034ClinicalTrials.gov